Grocery business Publix said on Tuesday that its is suspending the administration of the Johnson & Johnson COVID-19 vaccine at all of its pharmacy locations following guidance from the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA).
The CDC and FDA have issued a joint media statement with additional information about the Johnson & Johnson COVID-19 vaccine.
While a rare side effect, individuals who have received the Johnson & Johnson COVID-19 vaccine should contact their health care provider if they develop a severe headache, abdominal pain, leg pain or shortness of breath within three weeks, according to the CDC and FDA.
However, the customers can visit publix.com/covidvaccine to schedule an appointment for the Moderna COVID-19 vaccine, if currently available in their state.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV